<DOC>
	<DOC>NCT00162045</DOC>
	<brief_summary>The purpose of this Phase I-II multicenter clinical trial is to establish dosimetry and safety profiles for CARDIOLITE® (Technetium Tc99m Sestamibi) in pediatric subjects.</brief_summary>
	<brief_title>A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Mucocutaneous Lymph Node Syndrome</mesh_term>
	<mesh_term>Technetium Tc 99m Sestamibi</mesh_term>
	<criteria>Have been scheduled to undergo a clinically indicated rest or stress CARDIOLITE® MPI scan. Be able to comply with imaging requirements permitting completion of rest or stress CARDIOLITE® wholebody scans and SPECT imaging procedures without the use of sedation. Have a terminal illness where expected survival is ≤6 months Have known clinically significant laboratory abnormalities (creatine, liver enzymes, platelet count).</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>